Bimekizumab for patients with moderate to severe plaque psoriasis: 60-week results from BE ABLE 2, a randomized, double-blinded, placebo-controlled, phase 2b extension study — Andrew Blauvelt (2020) | RDL Network
Bimekizumab for patients with moderate to severe plaque psoriasis: 60-week results from BE ABLE 2, a randomized, double-blinded, placebo-controlled, phase 2b extension study
Andrew Blauvelt, Kim Papp, Joseph F. Merola, Alice B. Gottlieb, Nancy Cross, Cynthia Madden, Maggie Haitian Wang, Christopher L. Cioffi, Christopher Em Griffiths
Andrew Blauvelt, C. Leonardi, Boni E. Elewski, Jeffrey Crowley, Lyn Guenther, Melinda Gooderham, Richard G. Langley, Ronald Vender, Andreas Pinter, Christopher Em Griffiths, Yayoi Tada, Hany Elmaraghy, Renata Gontijo Lima, Gaia Gallo, L. Renda, Russel Burge, S.Y. Park, Baojin Zhu, Kim Papp
Robert Bissonnette, Lars Iversen, Howard Sofen, Christopher Em Griffiths, Peter Foley, Ricardo Romiti, Mary Bachinsky, S.T. Rottinghaus, Huaming Tan, James Proulx, Hernán Valdez, Pankaj Gupta, Lotus Mallbris, Robert Wołk
.webp){kind=small}
Discussion(0)
No comments yet. Be the first to comment.